Any consideration of GLP-1 therapy should involve comprehensive evaluation by an endocrinologist or appropriate specialist, with clear discussion of the investigational nature of this approach, potential risks, costs, and the importance of ongoing monitoring
The gap between the nominal patent expiration date and actual generic entry which can span anywhere from zero to six-plus years depending on litigation outcomes is where most of the analytical uncertainty lives
Noom defines a microdose as a dose of medication that is a fraction 25% or less of the typically prescribed maintenance dose
But since the advent of commercial drug manufacturing and the FDAs creation of a strict regulatory process for bringing safe, effective medications to market, compounding has been legally relegated to two scenarios, Robin Feldman, JD, a professor at the University of California College of the Law in San Francisco and an expert on pharmaceutical law, tells SELF
Scientific American described retatrutide as part of a new class of GLP-1-related drugs that aims at three hormone receptors rather than one
